InsiderTrades.com logo
Neal Pawar net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Neal Pawar Biography and Net Worth

Chief Operating Officer of Enfusion

Neal Pawar currently serves as Enfusion’s Chief Operating Officer and is a member of the firm’s Executive Committee. In his role, he oversees the Revenue, Product, Engineering, and Client Services organizations at Enfusion.

“Enfusion was designed by engineers and investors who grew up in the asset management industry; practitioners who had the vision to build a Software-as-a-Service platform from the ground up. As someone who has spent the majority of his career leading engineering and operations teams for some of the largest asset managers in the world, I could immediately see a level of client understanding and empathy that I simply haven’t seen in other platforms.”

A computer scientist by training, Neal has spent nearly 30 years in the financial services industry in a number of leadership roles. Neal has held senior operating roles on the buy-side of investment management, including as a Partner and CTO at quantitative firms D. E. Shaw & Co, and AQR Capital, as well as global operating roles as CIO of UBS Wealth Management and Group CIO of Deutsche Bank. Most recently he was COO and interim CEO of Qontigo, a provider of financial intelligence tools and indices for investment managers.

Neal is a member of the Board of Directors at CAIS group and a strategic advisor to Talos, a digital asset trading firm. He holds a B.S. in Computer Science from Brown University.

What is Neal Pawar's net worth?

The estimated net worth of Neal Pawar is at least $13.52 million as of March 5th, 2025. Mr. Pawar owns 1,217,067 shares of Enfusion stock worth more than $13,515,529 as of March 31st. This net worth estimate does not reflect any other investments that Mr. Pawar may own. Additionally, Mr. Pawar receives a salary of $469,390.00 as Chief Operating Officer at Enfusion. Learn More about Neal Pawar's net worth.

How old is Neal Pawar?

Mr. Pawar is currently 52 years old. There are 6 older executives and no younger executives at Enfusion. The oldest executive at Enfusion is Mr. Bradley Herring, Chief Financial Officer, who is 53 years old. Learn More on Neal Pawar's age.

What is Neal Pawar's salary?

As the Chief Operating Officer of Enfusion, Inc., Mr. Pawar earns $469,390.00 per year. There are 3 executives that earn more than Mr. Pawar. The highest earning executive at Enfusion is Mr. Oleg Movchan, CEO & Director, who commands a salary of $834,790.00 per year. Learn More on Neal Pawar's salary.

How do I contact Neal Pawar?

The corporate mailing address for Mr. Pawar and other Enfusion executives is , , . Enfusion can also be reached via phone at 312-253-9800 and via email at brian.murphy@icrinc.com. Learn More on Neal Pawar's contact information.

Has Neal Pawar been buying or selling shares of Enfusion?

During the past quarter, Neal Pawar has sold $363,173.72 in Enfusion stock. Most recently, Neal Pawar sold 14,560 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a transaction totalling $165,692.80. Following the completion of the sale, the chief operating officer now directly owns 1,217,067 shares of the company's stock, valued at $13,850,222.46. Learn More on Neal Pawar's trading history.

Who are Enfusion's active insiders?

Enfusion's insider roster includes Bronwen Bastone (Chief People Officer), Matthew Campobasso (General Counsel), Dan Groman (Chief Technology Officer), Bradley Herring (CFO), Roy Luo (Director), Oleg Movchan (CEO), Neal Pawar (Chief Operating Officer), and Deirdre Somers (Director). Learn More on Enfusion's active insiders.

Are insiders buying or selling shares of Enfusion?

During the last twelve months, insiders at the sold shares 29 times. They sold a total of 160,582 shares worth more than $1,648,833.48. The most recent insider tranaction occured on March, 6th when CEO Oleg Movchan sold 11,452 shares worth more than $130,438.28. Insiders at Enfusion own 36.4% of the company. Learn More about insider trades at Enfusion.

Information on this page was last updated on 3/6/2025.

Neal Pawar Insider Trading History at Enfusion

See Full Table

Neal Pawar Buying and Selling Activity at Enfusion

This chart shows Neal Pawar's buying and selling at Enfusion by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$363ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Enfusion Company Overview

Enfusion logo
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $11.11
Low: $11.09
High: $11.16

50 Day Range

MA: $11.18
Low: $11.01
High: $11.50

2 Week Range

Now: $11.11
Low: $7.83
High: $11.80

Volume

464,673 shs

Average Volume

553,276 shs

Market Capitalization

$1.43 billion

P/E Ratio

277.69

Dividend Yield

N/A

Beta

0.95